A history of quality
BHR Pharma, LLC is a pharmaceutical research & development company committed to bringing to market products using non-oral delivery systems with an emphasis on unmet and underserved medical needs. BHR is a wholly-owned subsidiary of Besins Healthcare, a fourth generation Besins family- owned business headquartered in Brussels, Belgium. Founded in 1885 in Paris, Besins has focused on transdermal delivery technology, with products now available in 93 countries around the globe.
BHR Pharma was founded in January 2008 and consolidates all global R&D functions for Besins Healthcare at our base in Herndon, Virginia, outside of Washington D.C. BHR is an affiliate of Ascend Therapeutics, Inc., Besins’ pharmaceutical sales and marketing entity in the US.
Focus on unmet needs
BHR applies its core expertise to the identification and selection of new product development opportunities. Our mission is to develop a robust pipeline of specialty drugs focusing on unmet medical needs. These include prostate cancer and related indications, neuroprotection in traumatic brain injury, as well as breast pain, breast cancer, and gynecomastia.
Enhanced Hydroalcoholic Gel (EHG®)
A number of BHR’s products leverage the Enhanced Hydroalcoholic Gel (EHG®) technology pioneered by Besins. The first EHG® product was commercially launched in 1975. Like other transdermal systems, the EHG® “patchless” transdermal delivery system avoids the gut and first-pass liver metabolism, increasing bioavailability in many instances and avoiding the generation of potentially toxic metabolites. Most of the BHR development pipeline focuses on products that use the EHG® technology and other parenteral formulations.